APLNR and metabolic disease: Several peptides are not yet approved but are under clinical investigation for nonmuscle indications, including apelin (antihypertensive) and the apelin–receptor agonist Elabela (cardioprotective and renoprotective), urocortin I (cardioprotective) and MOTS‐c (metabolic diseases) [106].